Development of a multicomponent implementation strategy to reduce upper gastrointestinal bleeding risk in patients using warfarin and antiplatelet therapy, and protocol for a pragmatic multilevel randomized factorial pilot implementation trial

Jacob E Kurlander, Danielle Helminski, Michael Lanham, Jennifer L Henstock, Kelley M Kidwell, Sarah L Krein, Sameer D Saini, Caroline R Richardson, Raymond De Vries, Kenneth Resnicow, Allison Laboon Ruff, David M Wallace, Elizabeth K Jones, Linda K Perry, Jacqueline Parsons, Nghi Ha, Tina Alexandris-Souphis, Dale Dedrick, Elizabeth Aldridge, Geoffrey D Barnes, Jacob E Kurlander, Danielle Helminski, Michael Lanham, Jennifer L Henstock, Kelley M Kidwell, Sarah L Krein, Sameer D Saini, Caroline R Richardson, Raymond De Vries, Kenneth Resnicow, Allison Laboon Ruff, David M Wallace, Elizabeth K Jones, Linda K Perry, Jacqueline Parsons, Nghi Ha, Tina Alexandris-Souphis, Dale Dedrick, Elizabeth Aldridge, Geoffrey D Barnes

Abstract

Background: The concomitant use of anticoagulant and antiplatelet medications increases the risk of upper gastrointestinal (GI) bleeding. Two underused evidence-based practices (EBPs) can reduce the risk: de-prescribe unnecessary antiplatelet therapy or initiate a proton pump inhibitor. We describe the development of a multicomponent intervention to increase use of these EBPs in patients treated with warfarin and followed by an anticoagulation monitoring service (AMS), and the design of a pilot pragmatic implementation trial.

Methods: A participatory planning group iteratively used Implementation Mapping and the Multiphase Optimization Strategy to develop implementation strategies and plan the trial. Informed by qualitative interviews with patients and clinicians, we drew on several implementation science theories, as well as self-determination theory, to design interventions. For patients, we developed an activation guide to help patients discuss the EBPs with their clinicians. For clinicians, we developed two electronic health record (EHR)-based interventions: (1) clinician notification (CN) consists of a templated message that identifies a patient as high risk, summarizes the EBPs, and links to a guidance statement on appropriate use of antiplatelet therapy. (2) Clinician notification with nurse facilitation (CN+NF) consists of a similar notification message but includes additional measures by nursing staff to support appropriate and timely decision-making: the nurse performs a chart review to identify any history of vascular disease, embeds indication-specific guidance on antiplatelet therapy in the message, and offers to assist with medication order entry and patient education. We will conduct a pilot factorial cluster- and individual-level randomized controlled trial with a primary objective of evaluating feasibility. Twelve clinicians will be randomized to receive either CN or CN+NF for all their patients managed by the AMS while 50 patients will be individually randomized to receive either the activation guide or usual care. We will explore implementation outcomes using patient and clinician interviews along with EHR review.

Discussion: This pilot study will prepare us to conduct a larger optimization study to identify the most potent and resource conscious multicomponent implementation strategy to help AMSs increase the use of best practices for upper GI bleeding risk reduction.

Trial registration: ClinicalTrials.gov NCT05085405 . Registered on October 19, 2021-retrospectively registered.

Keywords: Anticoagulation; Gastrointestinal hemorrhage; Gastroprotection; Guideline adherence; Implementation science; Nurse facilitation; Patient activation; Patient safety; Proton pump inhibitors; Quality of health care; Warfarin.

Conflict of interest statement

GDB receives consulting fees from Pfizer/Bristol-Myers Squibb, Jansen, and Acelis Connected Health. All other authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Logic model linking intervention activities to clinician behavior change and patient uptake of medication optimization
Fig. 2
Fig. 2
Study flow diagram for patients

References

    1. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral anticoagulant use. Am J Med. 2015;128(12):1300–1305.e2. doi: 10.1016/j.amjmed.2015.05.044.
    1. Lamberts M, Staerk L, Olesen JB, et al. Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life danish patients. J Am Heart Assoc. 2017;6(2):e004517. doi: 10.1161/JAHA.116.004517.
    1. Hippisley-Cox J, Coupland C. Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores. BMJ. 2014;349:g4606. doi: 10.1136/bmj.g4606.
    1. Ray WA, Chung CP, Murray KT, et al. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. Gastroenterology. 2016;151(6):1105–1112.e10. doi: 10.1053/j.gastro.2016.08.054.
    1. Schaefer JK, Errickson J, Li Y, et al. Adverse events associated with the addition of aspirin to direct oral anticoagulant therapy without a clear indication. JAMA Intern Med. 2021;181(6):817–824. doi: 10.1001/jamainternmed.2021.1197.
    1. Schaefer JK, Li Y, Gu X, et al. Association of adding aspirin to warfarin therapy without an apparent indication with bleeding and other adverse events. JAMA Intern Med. 2019;179(4):533–541. doi: 10.1001/jamainternmed.2018.7816.
    1. Budnitz DS, Shehab N, Lovegrove MC, Geller AI, Lind JN, Pollock DA. US emergency department visits attributed to medication harms, 2017-2019. JAMA. 2021;326(13):1299–1309. doi: 10.1001/jama.2021.13844.
    1. Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the american college of cardiology solution set oversight committee. J Am Coll Cardiol. 2021;77(5):629–658. doi: 10.1016/j.jacc.2020.09.011.
    1. Members WC, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021;77(4):e25–e197. doi: 10.1016/j.jacc.2020.11.018.
    1. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52(18):1502–1517. doi: 10.1016/j.jacc.2008.08.002.
    1. Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3(4):231–241. doi: 10.1016/S2468-1253(18)30037-2.
    1. Kurlander JE, Gu X, Scheiman JM, et al. Missed opportunities to prevent upper GI hemorrhage: the experience of the michigan anticoagulation quality improvement initiative. Vasc Med. 2019;24(2):153–155. doi: 10.1177/1358863X18815971.
    1. Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4(12):e006544. doi: 10.1136/bmjopen-2014-006544.
    1. Kurlander JE, Helminski D, Kokaly AN, et al. Barriers to guideline-based use of proton pump inhibitors to prevent upper gastrointestinal bleeding. Ann Fam Med. [InPress].
    1. Goyal P, Anderson TS, Bernacki GM, et al. Physician perspectives on deprescribing cardiovascular medications for older adults. J Am Geriatr Soc. 2020;68(1):78–86. doi: 10.1111/jgs.16157.
    1. Avery AJ, Rodgers S, Cantrill JA, et al. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet. 2012;379(9823):1310–1319. doi: 10.1016/S0140-6736(11)61817-5.
    1. Gill JM, Mainous AG, 3rd, Koopman RJ, et al. Impact of EHR-based clinical decision support on adherence to guidelines for patients on NSAIDs: a randomized controlled trial. Ann Fam Med. 2011;9(1):22–30. doi: 10.1370/afm.1172.
    1. Laine L, Connors L, Griffin MR, Curtis SP, Kaur A, Cannon CP. Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Aliment Pharmacol Ther. 2009;30(7):767–774. doi: 10.1111/j.1365-2036.2009.04090.x.
    1. Lanas A, Esplugues JV, Zapardiel J, Sobreviela E. Education-based approach to addressing non-evidence-based practice in preventing NSAID-associated gastrointestinal complications. World J Gastroenterol. 2009;15(47):5953–5959. doi: 10.3748/wjg.15.5953.
    1. Dreischulte T, Donnan P, Grant A, Hapca A, McCowan C, Guthrie B. Safer prescribing--a trial of education, informatics, and financial incentives. N Engl J Med. 2016;374(11):1053–1064. doi: 10.1056/NEJMsa1508955.
    1. Guthrie B, Kavanagh K, Robertson C, et al. Data feedback and behavioural change intervention to improve primary care prescribing safety (EFIPPS): multicentre, three arm, cluster randomised controlled trial. BMJ. 2016;354:i4079. doi: 10.1136/bmj.i4079.
    1. Hibbard JH, Greene J. What the evidence shows about patient activation: better health outcomes and care experiences; fewer data on costs. Health Aff (Millwood). 2013;32(2):207–214. doi: 10.1377/hlthaff.2012.1061.
    1. Wallis KA, Elley CR, Lee A, Moyes S, Kerse N. Safer Prescribing and Care for the Elderly (SPACE): protocol of a cluster randomized controlled trial in primary care. JMIR Res Protoc. 2018;7(4):e109. doi: 10.2196/resprot.9839.
    1. Nash DB. National Priorities and Goals. P T. 2009;34(2):61.
    1. World Health Organization. Patients for patient safety - partnerships for safer health care. Published online 2013. Accessed 30 June 2021.
    1. Kaboli PJ, Howren MB, Ishani A, Carter B, Christensen AJ, Vander Weg MW. Efficacy of patient activation interventions with or without financial incentives to promote prescribing of thiazides and hypertension control: a randomized clinical trial. JAMA Netw Open. 2018;1(8):e185017. doi: 10.1001/jamanetworkopen.2018.5017.
    1. Jacobson TA, Thomas DM, Morton FJ, Offutt G, Shevlin J, Ray S. Use of a low-literacy patient education tool to enhance pneumococcal vaccination rates. a randomized controlled trial. JAMA. 1999;282(7):646–650. doi: 10.1001/jama.282.7.646.
    1. Ibanez-Cuevas V, Lopez-Briz E, Guardiola-Chorro MT. NSAID induced Gastropathy Prevention Programme Group. Pharmacist intervention reduces gastropathy risk in patients using NSAIDs. Pharm World Sci. 2008;30(6):947–954. doi: 10.1007/s11096-008-9258-8.
    1. Wallis K, Tuckey R. Safer Prescribing and Care for the Elderly (SPACE): feasibility of audit and feedback plus practice mail-out to patients with high-risk prescribing. J Prim Health Care. 2017;9(2):145–152. doi: 10.1071/HC17018.
    1. Jackson AN, Kogut S. Use of electronic personal health records to identify patients at risk for aspirin-induced gastrointestinal bleeding. Consult Pharm. 2013;28(5):313–318. doi: 10.4140/TCP.n.2013.313.
    1. Entwistle VA, Mello MM, Brennan TA. Advising patients about patient safety: current initiatives risk shifting responsibility. Jt Comm J Qual Patient Saf. 2005;31(9):483–494. doi: 10.1016/s1553-7250(05)31063-4.
    1. Collins LM, Murphy SA, Nair VN, Strecher VJ. A strategy for optimizing and evaluating behavioral interventions. Ann Behav Med. 2005;30(1):65–73. doi: 10.1207/s15324796abm3001_8.
    1. Pinnock H, Barwick M, Carpenter CR, et al. Standards for Reporting Implementation Studies (StaRI) Statement. BMJ. 2017;356:i6795. doi: 10.1136/bmj.i6795.
    1. Fernandez ME, ten Hoor GA, van Lieshout S, et al. Implementation mapping: using intervention mapping to develop implementation strategies. Front Public Health. 2019;7. 10.3389/fpubh.2019.00158.
    1. Barnes GD, Nallamothu BK, Sales AE, Froehlich JB. Reimagining anticoagulation clinics in the era of direct oral anticoagulants. Circ Cardiovasc Qual Outcomes. 2016;9(2):182–185. doi: 10.1161/CIRCOUTCOMES.115.002366.
    1. Barnes GD, Kline-Rogers E, Graves C, et al. Structure and function of anticoagulation clinics in the United States: an AC forum membership survey. J Thromb Thrombolysis. 2018;46(1):7–11. doi: 10.1007/s11239-018-1652-z.
    1. Atkins L, Francis J, Islam R, et al. A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems. Implement Sci. 2017;12(1):77. doi: 10.1186/s13012-017-0605-9.
    1. Powell BJ, Waltz TJ, Chinman MJ, et al. A refined compilation of implementation strategies: results from the Expert Recommendations for Implementing Change (ERIC) project. Implement Sci. 2015;10(1):21. doi: 10.1186/s13012-015-0209-1.
    1. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42. doi: 10.1186/1748-5908-6-42.
    1. Kok G, Gottlieb NH, Peters GJY, et al. A taxonomy of behaviour change methods: an intervention mapping approach. Health Psychol Rev. 2016;10(3):297–312. doi: 10.1080/17437199.2015.1077155.
    1. Fogg B. A behavior model for persuasive design. In: Proceedings of the 4th International Conference on Persuasive Technology - Persuasive ’09. New York: Association for Computing Machinery Press; 2009. p. 1. 10.1145/1541948.1541999.
    1. Peters GJY, Ruiter RAC, Kok G. Threatening communication: a critical re-analysis and a revised meta-analytic test of fear appeal theory. Health Psychol Rev. 2013;7(sup1):S8–S31. doi: 10.1080/17437199.2012.703527.
    1. Deci EL, Ryan RM. Self-determination theory. In: Handbook of Theories of Social Psychology: Volume 1: SAGE Publications Ltd; 2012. p. 416–37. 10.4135/9781446249215.
    1. Ng JYY, Ntoumanis N, Thøgersen-Ntoumani C, et al. Self-determination theory applied to health contexts: a meta-analysis. Perspect Psychol Sci. 2012;7(4):325–340. doi: 10.1177/1745691612447309.
    1. Cialdini RB. Harnessing the science of persuasion. Harvard Business Review. Published online October 1, 2001. Accessed 17 Oct 2021.
    1. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890–898. doi: 10.1001/jamainternmed.2014.949.
    1. Bruyere Research Institute. Deprescribing information pamphlets - EMPOWER brochures. . Accessed 6Jul 2021.
    1. Martin P, Tamblyn R, Ahmed S, Tannenbaum C. An educational intervention to reduce the use of potentially inappropriate medications among older adults (EMPOWER study): protocol for a cluster randomized trial. Trials. 2013;14:80. doi: 10.1186/1745-6215-14-80.
    1. McGee J. CMS toolkit for making written material clear and effective. Centers for Medicare and Medicaid Services, U.S. Department of Health and Human Services. .
    1. Centers for Disease Control and Prevention. Simply put: a guide for creating easy-to-understand materials. Published online July 2010.
    1. Whittingham JRD, Ruiter RAC, Castermans D, Huiberts A, Kok G. Designing effective health education materials: experimental pre-testing of a theory-based brochure to increase knowledge. Health Educ Res. 2008;23(3):414–426. doi: 10.1093/her/cym018.
    1. Krug S. Rocket surgery made easy: the do-it-yourself guide to finding and fixing usability problems. 1st. ed. Berkley, CA: New Riders; 2009.
    1. Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17(1):88. doi: 10.1186/s12913-017-2031-8.
    1. Weiner BJ, Lewis CC, Stanick C, et al. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci. 2017;12:108. doi: 10.1186/s13012-017-0635-3.
    1. Wilson IB, Lee Y, Michaud J, Fowler FJ, Rogers WH. Validation of a new three-item self-report measure for medication adherence. AIDS Behav. 2016;20(11):2700–2708. doi: 10.1007/s10461-016-1406-x.
    1. Nevedal AL, Reardon CM, Opra Widerquist MA, et al. Rapid versus traditional qualitative analysis using the Consolidated Framework for Implementation Research (CFIR) Implement Sci. 2021;16(1):67. doi: 10.1186/s13012-021-01111-5.
    1. Hamilton AB, Finley EP. Qualitative methods in implementation research: An introduction. Psychiat Res. 2019;280:112516. doi: 10.1016/j.psychres.2019.112516.
    1. Snijders TAB, Bosker RJ. Multilevel analysis. In: An introduction to basic and advanced multilevel modeling. London: SAGE Publications Inc.; 2011.
    1. Teichert M, Griens F, Buijs E, Wensing M, De Smet PAGM. Effectiveness of interventions by community pharmacists to reduce risk of gastrointestinal side effects in nonselective nonsteroidal anti-inflammatory drug users. Pharmacoepidemiol Drug Saf. 2014;23(4):382–389. doi: 10.1002/pds.3587.
    1. Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the international consensus group. Ann Intern Med. 2019;171(11):805–822. doi: 10.7326/M19-1795.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe